Welcome to Dilaforette



Dilaforette is a drug development company developing a heparan sulphate mimetic, sevuparin, a proprietary drug derived from heparin. Sevuparin is an innovative, disease-modifying polysaccharide drug, with extensive world-wide IP protection.

Sevuparin is intended to be used as an anti-adhesive therapy and has therefore been designed to retain the anti-adhesives effects of heparin, while reducing the anti-coagulant properties. Sevuparin, with demonstrated strong anti-adhesive effects, has the potential to be of clinical use in several therapeutic conditions. Dilaforette is currently developing sevuparin for acute vaso-occlusive crises in sickle cell disease as the initial indication as well as for malaria.


Dilaforette, a Swedish drug development company, founded by leading scientists in malaria from Karolinska Institute as well as leading experts in the field of heparin and drug development from Uppsala University and the Swedish pharmaceutical industry together with Karolinska Innovation AB.

-> Read more under About us

  • News

    • Dilaforette presents results from exploratory Phase I/II clinical trial in uncomplicated malaria

      2014-05-30 10:06:35 STOCKHOLM, SWEDEN – May 30, 2014. Today, Dilaforette AB announced the results from an exploratory Phase I/II clinical trial in malaria with its candidate drug sevuparin. Sevuparin was studied in adult patients with uncomplicated falciparum malaria as adjunct treatment and was found to be safe and well tolerated. The study results indicates important early anti-adhesive effects with a potential to improve the outcome for patients with severe malaria, even though the primary efficacy endpoint was not met. Karolinska Development owns

    • Dilaforette AB announced today the appointment of Christina Herder as new CEO

      2014-01-22 14:03:07 STOCKHOLM, SWEDEN - January 22, 2014. Dilaforette AB, a company in Karolinska Development’s portfolio, announced today the appointment of Christina Herder as new CEO. Christina Herder, PhD, MBA, will bring over 20 years of experience in product development and business development from the pharmaceutical industry. “We are delighted that Christina is joining Dilaforette. Her expertise and experience will help us take the company forward to successful outcomes in malaria and sickle cell disease. I look forward to working with her over

    • Dilaforette – Phase II study with sevuparin for the treatment of severe malaria initiated

      2013-01-30 13:48:26 STOCKHOLM – January 30, 2013. Dilaforette, a Karolinska Development portfolio company, today announces that the company has approval from the regulatory authority in India to start a Phase II study with sevuparin in patients with moderate to severe malaria.   Dilaforette and its collaborator, The Mahidol Oxford Tropical Medicine Research Unit (MORU), plan to enroll 50 patients in India, where severe malaria remains an important problem. The primary objective of the study is to evaluate safety along with several efficacy parameters. The

    • Dilaforette is granted SEK 2.85m for development of sevuparin for the treatment of severe malaria

      2012-11-02 07:37:02 STOCKHOLM – November 2, 2012. Dilaforette announces today that it has been granted SEK 2.85m from the Swedish Governmental Agency for Innovation Systems, Vinnova, for the development of sevuparin, a new potential treatment for severe malaria.   Sevuparin is intended as an adjunctive therapy to anti-parasite medicines in order to prevent the infected red blood cells from obstructing blood vessels and thereby reducing mortality. Each year nearly 10 million people are diagnosed with severe malaria and about one million die of the disease. The

    • First patient has received low anticoagulant heparin (LAH) in Phase I/II

      2011-09-23 14:46:06 STOCKHOLM - September 23, 2011. Dilaforette, today announced that the first patient has received a dose of low anticoagulant heparin (LAH) in a Phase I/II study. This is the first time that low anticoagulant heparin (LAH) will be tested in malaria patients. The study is conducted in uncomplicated falciparum malaria patients with safety as the primary objective. In the next step efficacy in severe malaria patients will be tested. A total of 98 patients is planned to be included in the trial which